Myriad and AbbVie sign expanded agreement for Tumor BRACAnalysis CDx

Nov. 5, 2014

Myriad Genetics, Inc., has signed an expanded companion diagnostic agreement with AbbVie, Inc. a global biopharmaceutical company to use Tumor BRACAnalysis CDx as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib. The collaboration builds upon Myriad’s previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie’s ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer.

“We are excited to expand our collaboration with AbbVie, an emerging leader in oncology, and believe their choice of Myriad as a commercial partner speaks to our ability to provide high-quality, high-value companion diagnostic testing on a global basis.” says Peter Meldrum, president and CEO of Myriad.

Myriad’s Tumor BRACAnalysis CDx is a robust and accurate companion diagnostic test for identifying both germline (hereditary) and somatic (tumor) cancer-causing mutations in the BRCA1 and BRCA2 genes. Tumor BRACAnalysis CDx has undergone significant analytic validation and, according to company spokespersons, has been shown to identify up to 50 percent more patients with cancer-causing BRCA 1/2 mutations compared to germline testing alone.

Myriad is actively collaborating with leading pharmaceutical companies to use Tumor BRACAnalysis CDx as a companion diagnostic with certain PARP inhibitors, platinum-based drugs and other chemotherapeutic agents. In the United States, the testing will be done at the company’s laboratory in Salt Lake City. In Europe, the CE-marked test will be performed at the company’s Munich, Germany, laboratory. Read more about Myriad BRACAnalysis testing.

Read more